BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND DDR2, NTRKR3, 4921, ENSG00000162733, Q16832, MIG20a, TYRO10
18 results:

  • 1. Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.
    Sala M; Allain N; Moreau M; Jabouille A; Henriet E; Abou-Hammoud A; Uguen A; Di-Tommaso S; Dourthe C; Raymond AA; Dupuy JW; Gerard E; Dugot-Senant N; Rousseau B; Merlio JP; Pham-Ledart A; Vergier B; Tartare-Deckert S; Moreau V; Saltel F
    Oncogene; 2022 Apr; 41(18):2571-2586. PubMed ID: 35322197
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [The imaging signs and significances of the enlargement of the infraorbital nerve and the frontal nerve in orbital lymphoproliferative diseases].
    Wang Y; Zhuo W; Hei Y; Tong QZ; Li TY
    Zhonghua Yan Ke Za Zhi; 2020 Nov; 56(11):832-838. PubMed ID: 33152841
    [No Abstract]    [Full Text] [Related]  

  • 3. Over expression of CDK4 and MDM2 in a patient with recurrent ALK-negative mediastinal inflammatory myofibroblastic tumor: A case report.
    Hou TC; Wu PS; Huang WY; Yang YT; Tan KT; Liu SH; Chen YJ; Chen SJ; Su YW
    Medicine (Baltimore); 2020 Mar; 99(12):e19577. PubMed ID: 32195970
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Circ-LAMP1 promotes T-cell lymphoblastic lymphoma progression via acting as a ceRNA for miR-615-5p to regulate ddr2 expression.
    Deng L; Liu G; Zheng C; Zhang L; Kang Y; Yang F
    Gene; 2019 Jun; 701():146-151. PubMed ID: 30922709
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Primary and Metastatic Melanoma With NTRK Fusions.
    Lezcano C; Shoushtari AN; Ariyan C; Hollmann TJ; Busam KJ
    Am J Surg Pathol; 2018 Aug; 42(8):1052-1058. PubMed ID: 29683819
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Targeted therapy in nonsmall cell lung cancer.
    Puri T
    Indian J Cancer; 2017; 54(1):83-88. PubMed ID: 29199670
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Down's Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship.
    Dey N; Krie A; Klein J; Williams K; McMillan A; Elsey R; Sun Y; Williams C; De P; Leyland-Jones B
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28590426
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Molecular genetic studies on EGFR, KRAS, BRAF, ALK, PIK3CA, PDGFRA, and ddr2 in primary pulmonary adenoid cystic carcinoma.
    Huo Z; Wu H; Li S; Liang Z
    Diagn Pathol; 2015 Sep; 10():161. PubMed ID: 26373952
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
    Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
    Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Prognostic and predictive biomarkers in lung cancer. A review.
    Thunnissen E; van der Oord K; den Bakker M
    Virchows Arch; 2014 Mar; 464(3):347-58. PubMed ID: 24420742
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. From platinum compounds to targeted therapies in advanced thoracic malignancies.
    Jakopovic M; Thomas A; Lopez-Chavez A
    Anticancer Res; 2014 Jan; 34(1):477-82. PubMed ID: 24403504
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Emerging protein kinase inhibitors for non-small cell lung cancer.
    Liu SV; Subramaniam D; Cyriac GC; Abdul-Khalek FJ; Giaccone G
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):51-65. PubMed ID: 24354593
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [Advances of molecular targeted therapy in squamous cell lung cancer].
    Ma L; Zhang S
    Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):671-5. PubMed ID: 24345494
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Targeted therapy for NSCLC with driver mutations.
    Minuti G; D'Incecco A; Cappuzzo F
    Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
    Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
    Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. New targetable oncogenes in non-small-cell lung cancer.
    Oxnard GR; Binder A; Jänne PA
    J Clin Oncol; 2013 Mar; 31(8):1097-104. PubMed ID: 23401445
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma.
    Willenbrock K; Küppers R; Renné C; Brune V; Eckerle S; Weidmann E; Bräuninger A; Hansmann ML
    Haematologica; 2006 May; 91(5):596-604. PubMed ID: 16670065
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma.
    Renné C; Willenbrock K; Küppers R; Hansmann ML; Bräuninger A
    Blood; 2005 May; 105(10):4051-9. PubMed ID: 15677564
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.